492 related articles for article (PubMed ID: 20483498)
1. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
3. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
4. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
5. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
6. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
[TBL] [Abstract][Full Text] [Related]
7. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
10. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
[TBL] [Abstract][Full Text] [Related]
11. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
12. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
14. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
Wei L; Kao JH
Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
[TBL] [Abstract][Full Text] [Related]
15. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Lin CC; Bair MJ; Liu CY; Lin ZY; Chen CJ; Chen MJ; Chu CH; Wang HY; Shih SC; Wang TE
Medicine (Baltimore); 2019 Jan; 98(1):e13818. PubMed ID: 30608393
[TBL] [Abstract][Full Text] [Related]
16. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
17. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
18. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
20. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
